Motley Fool Wealth Management LLC Sells 9,117 Shares of DexCom, Inc. (NASDAQ:DXCM)

Key Points

• Motley Fool Wealth Management LLC reduced its stake in DexCom, Inc. by 3.5%, selling 9,117 shares, which leaves it with 251,291 shares, constituting approximately 1.0% of their total holdings.
• In the first quarter, several hedge funds showed increased interest in DexCom, with Golden State Wealth Management LLC boosting its holdings by 211.2% to own 389 shares, valued at $27,000.
• Equities research analysts generally have a positive outlook on DexCom, with Citigroup recently raising its target price to $102.00 and maintaining a "buy" rating.

Motley Fool Wealth Management LLC trimmed its position in shares of DexCom, Inc. (NASDAQ:DXCM - Free Report) by 3.5% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 251,291 shares of the medical device company's stock after selling 9,117 shares during the period. DexCom comprises approximately 1.0% of Motley Fool Wealth Management LLC's portfolio, making the stock its 25th biggest holding. Motley Fool Wealth Management LLC owned about 0.06% of DexCom worth $17,161,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors have also modified their holdings of the company. Golden State Wealth Management LLC raised its holdings in DexCom by 211.2% during the first quarter. Golden State Wealth Management LLC now owns 389 shares of the medical device company's stock valued at $27,000 after buying an additional 264 shares in the last quarter. Private Trust Co. NA raised its holdings in DexCom by 99.4% during the first quarter. Private Trust Co. NA now owns 672 shares of the medical device company's stock valued at $46,000 after buying an additional 335 shares in the last quarter. Farther Finance Advisors LLC raised its holdings in DexCom by 29.3% during the first quarter. Farther Finance Advisors LLC now owns 3,100 shares of the medical device company's stock valued at $209,000 after buying an additional 702 shares in the last quarter. Dynamic Advisor Solutions LLC raised its holdings in DexCom by 34.2% during the first quarter. Dynamic Advisor Solutions LLC now owns 5,235 shares of the medical device company's stock valued at $357,000 after buying an additional 1,333 shares in the last quarter. Finally, Stonebridge Financial Group LLC raised its holdings in DexCom by 944.5% during the first quarter. Stonebridge Financial Group LLC now owns 3,217 shares of the medical device company's stock valued at $220,000 after buying an additional 2,909 shares in the last quarter. 97.75% of the stock is currently owned by hedge funds and other institutional investors.

DexCom Stock Performance

NASDAQ DXCM remained flat at $79.96 during trading on Thursday. The company's stock had a trading volume of 2,234,124 shares, compared to its average volume of 3,910,180. The company has a debt-to-equity ratio of 0.48, a quick ratio of 1.35 and a current ratio of 1.52. The stock has a fifty day moving average price of $83.28 and a 200 day moving average price of $80.19. The firm has a market capitalization of $31.36 billion, a P/E ratio of 55.53, a price-to-earnings-growth ratio of 1.68 and a beta of 1.43. DexCom, Inc. has a 12 month low of $57.52 and a 12 month high of $93.25.

DexCom (NASDAQ:DXCM - Get Free Report) last released its quarterly earnings data on Wednesday, July 30th. The medical device company reported $0.48 earnings per share for the quarter, beating analysts' consensus estimates of $0.45 by $0.03. The company had revenue of $1.16 billion for the quarter, compared to the consensus estimate of $1.13 billion. DexCom had a return on equity of 30.41% and a net margin of 13.29%. The company's quarterly revenue was up 15.2% on a year-over-year basis. During the same period in the previous year, the business earned $0.43 earnings per share. Equities research analysts expect that DexCom, Inc. will post 2.03 EPS for the current fiscal year.

Insider Activity

In other news, EVP Michael Jon Brown sold 10,000 shares of DexCom stock in a transaction that occurred on Friday, May 23rd. The shares were sold at an average price of $84.28, for a total value of $842,800.00. Following the completion of the transaction, the executive vice president owned 95,602 shares in the company, valued at approximately $8,057,336.56. The trade was a 9.47% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Nicholas Augustinos sold 3,672 shares of DexCom stock in a transaction that occurred on Monday, June 16th. The shares were sold at an average price of $82.80, for a total transaction of $304,041.60. Following the completion of the transaction, the director owned 33,411 shares of the company's stock, valued at $2,766,430.80. This trade represents a 9.90% decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 28,656 shares of company stock worth $2,412,191. 0.32% of the stock is currently owned by insiders.

Wall Street Analysts Forecast Growth

Several equities analysts have weighed in on the company. Canaccord Genuity Group restated a "buy" rating and set a $106.00 target price on shares of DexCom in a report on Friday, August 1st. Oppenheimer raised their price target on DexCom from $95.00 to $102.00 and gave the company an "outperform" rating in a research report on Thursday, July 31st. Citigroup reaffirmed a "buy" rating and issued a $102.00 price target (up from $82.00) on shares of DexCom in a research report on Thursday, May 22nd. The Goldman Sachs Group assumed coverage on DexCom in a research report on Friday, May 30th. They issued a "buy" rating and a $104.00 price target on the stock. Finally, Mizuho raised their price target on DexCom from $95.00 to $100.00 and gave the company an "outperform" rating in a research report on Wednesday, July 16th. Four equities research analysts have rated the stock with a hold rating, sixteen have issued a buy rating and three have assigned a strong buy rating to the stock. According to MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus target price of $99.89.

DexCom Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.